Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?

Exelixis (EXEL) announced positive top-line Phase III results from its STELLAR-303 study for zanzalintinib in combination with Tecentriq for metastatic colorectal cancer, demonstrating a statistically significant improvement in overall survival. This progress is crucial for EXEL, which is currently heavily reliant on its lead drug Cabometyx, facing intensifying competition in the renal cell carcinoma market. While other zanzalintinib trials are advancing and new ones initiated, the company decided against proceeding with the Phase III portion of STELLAR-305. Despite EXEL shares gaining 14% year-to-date, the stock trades at an expensive 4.09x forward sales, significantly above the biotech industry average.

Analysis

Exelixis (EXEL) has reported a significant clinical victory with its investigational TKI, zanzalintinib. The late-stage STELLAR-303 study met a primary endpoint, demonstrating a statistically significant improvement in overall survival for metastatic colorectal cancer patients when zanzalintinib was combined with Tecentriq, compared to the standard-of-care, regorafenib. This positive result is critical for the company as it seeks to diversify its revenue stream beyond its primary drug, Cabometyx, which faces intensifying competition in the renal cell carcinoma (RCC) space from established combination therapies by Merck (MRK), Pfizer (PFE), and Bristol Myers (BMY). However, the pipeline progress is not uniformly positive; the company has strategically discontinued the phase III portion of its STELLAR-305 trial due to emerging competition and a reassessment of commercial opportunities. Despite the stock's 14% year-to-date gain, which outperforms the broader biotech industry's 0.9% decline, valuation appears stretched. EXEL currently trades at a forward price-to-sales ratio of 4.09x, a premium to both its own historical mean of 3.64x and the industry average of 1.59x. This is coupled with mixed analyst revisions, as the 2025 bottom-line estimate has risen slightly while the 2026 estimate has been trimmed.

Key Decisions for Investors

• The positive STELLAR-303 trial data materially de-risks the zanzalintinib pipeline, providing a potential long-term growth driver to offset the competitive pressures on Cabometyx.
• Investors should weigh the promising clinical developments against the stock's premium valuation, as its 4.09x forward P/S ratio may already price in a significant portion of this success.
• Monitor upcoming catalysts closely, particularly the final analysis of the second primary endpoint in the STELLAR-303 trial and data from the STELLAR-304 study in nccRCC, as these will be crucial for defining the drug's ultimate market potential.